Other Events ·
Tenax Therapeutics, Inc. entered into a Supply Agreement with Orion Corporation on June 29, 2026, designating Orion as…
TENXTenax Therapeutics, Inc.
Tenax Therapeutics, Inc. entered into a Supply Agreement with Orion Corporation on June 29, 2026, designating Orion as the primary supplier of orally administered levosimendan for development and commercial purposes. The agreement includes cost-sharing provisions for scaling up manufacturing capabilities and has an initial five-year term. Concurrently, the parties entered into a Sixth Amendment to their existing License Agreement, which extends the regulatory approval milestone for the product in the United States to December 31, 2035. Tenax Therapeutics, Inc. is a biotechnology company focused on the development of therapeutic products.